NCT03492398View on ClinicalTrials.gov

A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

March 21, 2019

Study Completion Date

May 28, 2019

Conditions
Atopic Dermatitis
Interventions
DRUG

HY209

6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Shaperon
All Listed Sponsors
lead

Shaperon

INDUSTRY

NCT03492398 - A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis | Biotech Hunter | Biotech Hunter